Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06617286 · ClinicalTrials.gov registry record · Phase 1
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
A Phase 1 study, sponsored by New York Medical College.
- Not yet
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT06617286: Clinical Trial Phase 1 study, sponsored by New York Medical College.
NCT06617286 is a Phase 1 study that has not yet begun recruiting, run by New York Medical College. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06617286, a Phase 1 study, has not yet begun recruiting, sponsored by New York Medical College.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.
Primary Outcome
To evaluate the incidence of adverse events related to autologous CD30+ CAR T-cell infusions including not limited to infusions related reactions (IRR) (CTCAE 5.0), cytokine release syndrome (CRS) (ASCTC), and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) (ASCTC) and all general grade 3-5 toxicities (CTCAE 5.0) in children, adolescent, and young adult patients with poor-risk CD30+ cHL following MAC AutoHSCT.
Interventions
- BIOLOGICAL CD30 CAR T-cell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2026-12-01 |
| Est. Completion | 2040-12-31 |
| Phase | Phase 1 |
What is known before NCT06617286 opens enrollment
NCT06617286 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 1 intervention - of which CD30 CAR T-cell is the first listed.
NCT06617286 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06617286 about?
NCT06617286 is a clinical study titled "CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma". Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.
What is the current status of trial NCT06617286?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2026-12-01. Estimated completion is 2040-12-31.
What interventions are being tested in trial NCT06617286?
The interventions under investigation include: CD30 CAR T-cell (BIOLOGICAL).
Who is sponsoring clinical trial NCT06617286?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06617286's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI